We are live on ! Find out more
ZNTL icon

Zentalis Pharmaceuticals
ZNTL

102 hedge funds and large institutions have $102M invested in Zentalis Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 30 increasing their positions, 28 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

604% more call options, than puts

Call options by funds: $971K | Put options by funds: $138K

170% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 10

85% more capital invested

Capital invested by funds: $54.9M → $102M (+$46.8M)

19% more funds holding

Funds holding: 86 → 102 (+16)

5.23% more ownership

Funds ownership: 56.18% → 61.41% (+5.2%)

7% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 28

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
1.26%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
27
Increased
30
Reduced
28
Closed
10
Calls
$971K
Puts
$138K
Net Calls
+$833K
Net Calls Change
+$806K

Top Buyers

1
SCM
Squadron Capital Management
Illinois
+$9.38M
2
Two Sigma Investments
Two Sigma Investments
New York
+$3.84M
3
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$1.6M
4
Millennium Management
Millennium Management
New York
+$1.59M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$1.45M

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$2.44M
2
GCP
GSA Capital Partners
United Kingdom
-$1.42M
3
UBS Group
UBS Group
Switzerland
-$1.34M
4
Morgan Stanley
Morgan Stanley
New York
-$1.17M
5
WP
Woodline Partners
California
-$683K
Name Holding Trade Value Shares
Change 		Change in
Stake
JP Morgan Chase
51
JP Morgan Chase
New York
$242K -$186K -71,881 -39%
Simplex Trading
52
Simplex Trading
Illinois
$231K +$255K +98,554 New
Point72 Asset Management
53
Point72 Asset Management
Connecticut
$222K -$14K -5,436 -5%
GCM
54
Graham Capital Management
Connecticut
$216K +$3.92K +1,517 +2%
Wealth Enhancement Advisory Services
55
Wealth Enhancement Advisory Services
Minnesota
$207K -$133K -51,667 -40%
BCM
56
Bridgeway Capital Management
Texas
$181K – – –
Citigroup
57
Citigroup
New York
$181K +$200K +77,255 New
4WM
58
49 Wealth Management
Texas
$155K -$11.6K -4,510 -6%
Federated Hermes
59
Federated Hermes
Pennsylvania
$153K +$79.9K +30,946 +90%
Commonwealth Equity Services
60
Commonwealth Equity Services
Massachusetts
$144K – – –
HF
61
HRT Financial
New York
$122K +$135K +52,185 New
Charles Schwab
62
Charles Schwab
California
$120K +$132K +51,087 New
RC
63
RBF Capital
California
$117K -$77.5K -30,000 -38%
American Century Companies
64
American Century Companies
Missouri
$114K +$92.2K +35,692 +277%
OAC
65
OMERS Administration Corp
Ontario, Canada
$112K +$123K +47,700 New
BHCM
66
Brevan Howard Capital Management
Jersey
$110K +$122K +47,063 New
Tudor Investment Corp
67
Tudor Investment Corp
Connecticut
$81.5K – – –
QC
68
Quadrature Capital
United Kingdom
$78K -$269K -104,236 -76%
PAG
69
Private Advisor Group
New Jersey
$73.6K +$81.3K +31,472 New
Squarepoint
70
Squarepoint
New York
$71.8K -$199K -77,043 -72%
HT
71
Headlands Technologies
Illinois
$70K +$77.2K +29,899 New
RCM
72
Regency Capital Management
Hawaii
$69K – – –
SOW
73
State of Wyoming
Wyoming
$66.6K +$73.5K +28,466 New
CA
74
Carson Advisory
Georgia
$54.5K -$517 -200 -0.9%
Raymond James Financial
75
Raymond James Financial
Florida
$53.6K +$7.75K +3,000 +15%
1 2
3
4 5

ZNTL Hedge Fund Activity: Q1 2026 in Review

102 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q1 2026, worth a combined $102M — up 85% from $54.9M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new ZNTL positions and 10 closed out — a net gain of 17 holders — while 30 added to existing stakes and 28 trimmed.

The largest buyer was Squadron Capital Management, opening a new position worth an estimated $9.38M. The largest seller was Renaissance Technologies, cutting an estimated $2.44M.

  • 102 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q1 2026, up from 86 in Q4 2025.
  • Funds reported $102M of Zentalis Pharmaceuticals stock for Q1 2026, up 85% quarter-over-quarter.
  • 27 funds opened new Zentalis Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +17 holders.
  • The largest Zentalis Pharmaceuticals buyer in Q1 2026 was Squadron Capital Management, an estimated $9.38M added.
  • The largest Zentalis Pharmaceuticals seller in Q1 2026 was Renaissance Technologies, an estimated $2.44M sold.

Based on aggregated 13F filings for Q1 2026.